Combined Treatment with Ursodeoxycholic Acid and Pioglitazone in a Patient with NASH Associated with Type 2 Diabetes and Psoriasis

Digestive Diseases and Sciences

Volumn 48, Issue 11, 2003, Pages 2182-2186

  Itoh, Susumu ^a   Kanazuka, Azuma ^a   Akimoto, Takahide ^a  

^a Kasori Hospital   (Japan)

Author keywords

NASH; Pioglitazone; Psoriasis; Type 2 diabetes; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; COLECALCIFEROL; GAMMA GLUTAMYLTRANSFERASE; PIOGLITAZONE; URSODEOXYCHOLIC ACID;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CYTODIAGNOSIS; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; TREATMENT OUTCOME;

AGED; CHOLAGOGUES AND CHOLERETICS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FATTY LIVER; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PSORIASIS; THIAZOLIDINEDIONES; URSODEOXYCHOLIC ACID;

EID: 0347992792     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000004523.51779.7c     Document Type: Article

References (43)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980
2. Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:3-16, 2001
3. Kuwana B, Urayama O, Kawai K: Reference value and cut-off value for diagnosis of insulin resistance in type 2 diabetes mellitus. Rinsho Byori 50:398-403, 2002
4. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
5. Lonardo A, Loria P, Carulli N: Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST.E.N.A. study. Dig Liver Dis 33:86-87, 2001
6. Diwok K, Leithäuser W, Nowotny P, Moldenhauer E, Dabels J: Liver changes in psoriasis vulgaris. Dtsch Z Verdau Stoffwechselkr 31:231-235, 1971
7. Zachariae H, Søgaard H: Liver biopsy in psoriasis. A controlled study. Dermatologica 146:149-155, 1973
8. Shapiro HA, Trowbridge JO, Lee JC, Maibach HI: Liver disease in psoriatics-An effect of methotrexate therapy? Arch Dermatol 110:547-551, 1974
9. Gyurcsovics K, Betrók L: Role of bile acids and endotoxins in the pathogenesis and therapy of psoriasis. Orv Hetil 141:915-917, 2000
10. Yamaguchi Y, Itami S, Nishida K, Ando Y, Okamoto S, Hosokawa K, Yoshikawa K: Taurin-conjugated ursodeoxycholic acid has a reversible inhibitory effect on human keratinocyte growth. J Dermatol Sci 18:35-42, 1998
11. Pershadsingh HA: Pharmacological peroxisome proliterator-activated receptor gamma ligands: emerging clinical indications beyond diabetes. Expert Opin Investig Drugs 8:1859-1872, 1999
12. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW: Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136:609-616, 2000
13. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917, 1998
14. Kohlroser J, Mathai J, Reichheld J, Bonner BF, Bonkovsky HL: Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272-276, 2000
15. Abdelmalek M, Ludwig J, Lindor KD: Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 20:127-130, 1995
16. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hapatology 23:1464-1467, 1996
17. Angulo P, Lindor KD: Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 21:81-88, 2001
18. Guma G, Viola L, Thomé M, Galdame O, Alvarez E: Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a protective clinical controlled trial. Hepatology 26:387A, 1997 (abstract)
19. Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G: Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. Hepatology 28:386A, 1998 (abstract)
20. Youssef W, McCullough AJ: Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 13:17-30, 2002
21. McCullough AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 34:255-262, 2002
22. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145, 1997
23. Bellentani S, Chao YC, Ferretti I, Panini R, Tiribelli C: Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid compositions in rats. Biochem Biophys Res Commun 220:479-483, 1996
24. Oliva L, Beaugé F, Choquart D, Montet AM, Guitaoui M, Montet JC: Ursodeoxycholate alleviates alcoholic fatty liver damage in rats. Alcohol Clin Exp Res 22:1538-1543, 1998
25. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL: A pilot study of a thiazolodinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519-525, 2001
26. O'Moore-Sullivan TM, Prins JB: Thiazolidinediones and type 2 diabetes: New drugs for an old disease. Med J Aust 176:381-386, 2002
27. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diametes. Metabolism 51:314-317, 2002
28. Baba S: Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 17:166-189, 2001
29. Peters AL: Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. Am J Manag Care 7(3 suppl):S87-S95, 2001
30. Neuschwander-Tetri BA, Brunt EM, Bacon BR: Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with the PPARγ agonist rosiglitazone. Hepatology 36:379A, 2002
31. Azuma T, Tomita K, Kato S, Adachi M, Inokuchi S, Kitamura N, Nishimura T, Ishii H: A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis. Hepatology 36:406A, 2002
32. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
33. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L: Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
34. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912, 1999
35. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K: Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23:1067-1071, 2000
36. Stumvoll M, Häring HU: Glitazones: Clinical effects and molecular mechanisms. Ann Med 34:217-224, 2002
37. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K: Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 48:81-86, 2001
38. Suou T, Yamada S, Hosho K, Yoshokawa H, Kawasaki H: Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease. Hepatology 23:1154-1158, 1996
39. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N: Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291:55-61, 2002
40. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122:1924-1940, 2002
41. May LD, Lefkowitch JH, Kram MT, Rubin DE: Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 136:449-452, 2002
42. Chase MP, Yarze JC: Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 97:502-503, 2002
43. Maeda K: Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 135:306, 2001